Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: The optimal ablation strategy for persistent atrial fibrillation (AF) remains unclear. METHODS AND RESULTS: This multicentre randomized study compared circumferential pulmonary vein ablation+linear ablation (control arm) versus circumferential pulmonary vein ablation+linear ablation+complex fractionated atrial electrogram (CFAE) ablation (CFAE arm) in patients with persistent AF. Circumferential pulmonary vein ablation was performed followed by roof and mitral isthmus ablation, before CFAE ablation in the CFAE arm. Ablation strategy was maintained at the first redo procedure. Sixty-five patients were recruited in each arm. The mean age was 61±10 years, 75% were men, median AF duration was 2 years, 42% had long-lasting persistent AF, 68% had associated cardiovascular disease, mean left atrial dimension was 46±6 mm, and median CHA2DS2-VASc score was 2. Ablation and procedure times were significantly longer in the CFAE arm (70±20 versus 55±17; 201±35 versus 152±45 minutes; P<0.005). After a mean follow-up of 35±5 months, single-procedural success off antiarrhythmic drugs at 12 months (CFAE: 30/65 [46%] versus control: 37/65 [57%]; P=0.29) and multiprocedural success (CFAE: 51/65 [78%] versus control: 52/65 [80%]; P=1.0) were not significantly different. At the first redo procedure, patients in the CFAE arm had a higher incidence of organized atrial tachycardia/flutter (24/33 [73%] versus 11/31 [35%]; P=0.005) and gap-related macro-re-entrant flutter (8/33[24%] versus 1/31[3%]; P=0.03). Early recurrence of atrial arrhythmia was an independent predictor of late recurrence. CONCLUSIONS: CFAE ablation did not confer incremental benefit when performed in addition to circumferential pulmonary vein ablation and linear ablation. It was associated with a higher incidence of gap-related flutter. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01711047.

Original publication

DOI

10.1161/CIRCEP.114.002504

Type

Journal article

Journal

Circ Arrhythm Electrophysiol

Publication Date

12/2015

Volume

8

Pages

1316 - 1324

Keywords

anti-arrhythmia agents, atrial fibrillation, catheter ablation, heart atria, pulmonary veins, Action Potentials, Aged, Anti-Arrhythmia Agents, Atrial Fibrillation, Atrial Flutter, Catheter Ablation, Electrophysiologic Techniques, Cardiac, England, Female, Heart Rate, Humans, Male, Middle Aged, Mitral Valve, Predictive Value of Tests, Prospective Studies, Pulmonary Veins, Recurrence, Reoperation, Risk Factors, Time Factors, Treatment Outcome